Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease

AIMS: Voxelotor (previously GBT440) is a haemoglobin (Hb) modulator that increases Hb‐oxygen affinity, thereby reducing Hb polymerization and sickling of red blood cells (RBCs), being developed as a once‐daily oral drug to treat sickle cell disease (SCD). This first‐in‐human study evaluated the safe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Clin Pharmacol
Main Authors: Hutchaleelaha, Athiwat, Patel, Mira, Washington, Carla, Siu, Vincent, Allen, Elizabeth, Oksenberg, Donna, Gretler, Daniel D., Mant, Timothy, Lehrer‐Graiwer, Josh
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6533444/
https://ncbi.nlm.nih.gov/pubmed/30743314
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13896
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados